The BR2 peptide associated with 2-aminoethyl dihydrogen phosphate is a formulation with antiproliferative potential for a triple-negative breast cancer model
Laertty Garcia de Sousa Cabral, Henrique Hesse, Katielle Albuquerque Freire, Cyntia Silva Oliveira, Cibele Nicolaski Pedron, Monique Gonçalves Alves, Julio Pacheco Carlstron, Jean‐Luc Poyet, Vani Xavier Oliveira, Durvanei Augusto Maria
Abstract
P + BR2 promoted tumor cells arrest in the G0/G1 phases. Interestingly, both treatments modulated the expression of markers CD44, CD34, CD24, cyclin D1, and Bcl-2, increased p21, Bax, and released cytochrome c. The association proved to be more effective, providing modulation of proteins involved in cell death and senescence, more pronounced cytotoxicity for tumor cells compared to normal cells, and the reduction of markers related to aggressiveness profile, progression, and tumor metastasis.
Topics & Concepts
Triple-negative breast cancerCancer researchCytotoxicityProgrammed cell deathBreast cancerCancerMetastasisChemistryViability assayBiologyApoptosisMedicineInternal medicineBiochemistryIn vitroAdvanced biosensing and bioanalysis techniquesRNA Interference and Gene DeliveryMachine Learning in Bioinformatics